Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 20,596 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Completed Phase 3 Interventional

Motivation and Patch Treatment for HIV-positive Smokers

NCT00551720
View directory record Official record
Conditions
HIV Infections, Smoking Cessation
Interventions
Standard Care, Motivational Enhancement
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
5
States / cities
Fall River, Massachusetts • New Bedford, Massachusetts • Pawtucket, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 17, 2026, 10:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

NCT01535924
View directory record Official record
Conditions
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
Interventions
gemcitabine hydrochloride, bendamustine hydrochloride
Drug
Lead sponsor
Beth Christian
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 17, 2026, 10:19 AM EDT
Completed Phase 4 Interventional

Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients

NCT00106379
View directory record Official record
Conditions
HIV Infections
Interventions
Truvada (tenofovir DF + emtricitabine), Emtriva (emtricitabine), Viread (tenofovir DF)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Fort Lauderdale, Florida • Vero Beach, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Oct 17, 2026, 10:19 AM EDT
Recruiting Phase 2 Interventional

METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)

NCT07699380
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Metabolic Diseases, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases, Diabetes Melletus, Type 1, Nutritional and Metabolic Diseases, Combination Therapy
Interventions
AMX0035, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 69 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 10:19 AM EDT
Completed Phase 1 Interventional Results available

sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS

NCT02239562
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
sPIF, Placebo
Drug
Lead sponsor
Christopher O'Brien, MD
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Miami, Florida • Cherry Hill, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 17, 2026, 10:19 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid

NCT02226146
View directory record Official record
Conditions
Pemphigoid, Bullous
Interventions
Bertilimumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Iowa City, Iowa • Buffalo, New York • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 17, 2026, 10:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Study of Lupus Patients and Their Families

NCT00235378
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
Not listed
Enrollment
2,356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 17, 2026, 10:19 AM EDT
Completed Not applicable Interventional

An Outpatient Study of Automated Blood Glucose Control With an Insulin-Only Bionic Pancreas

NCT02536950
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Fixed set point, Variable set point
Device
Lead sponsor
Bruce A. Buckingham
Other
Eligibility
18 Years to 44 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 17, 2026, 10:19 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
6 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 17, 2026, 10:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Family Access to Care Study (FACS)

NCT00582218
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2009 · Synced Oct 17, 2026, 10:19 AM EDT
Recruiting Phase 3 Interventional

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
Mezagitamab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
25
States / cities
Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 17, 2026, 10:19 AM EDT
Completed Phase 2 Interventional Results available

Chloroquine for Reducing Immune Activation in HIV- Infected Individuals

NCT00819390
View directory record Official record
Conditions
HIV Infections
Interventions
Chloroquine, Placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 17, 2026, 10:19 AM EDT
Completed Not applicable Interventional

Mindfulness Meditation in Treating Insomnia in Multiple Sclerosis

NCT03949296
View directory record Official record
Conditions
Insomnia Chronic, Multiple Sclerosis
Interventions
Mindfulness Intervention, Sleep Hygiene
Behavioral
Lead sponsor
Griffin Hospital
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 17, 2026, 10:19 AM EDT
Recruiting Early Phase 1 Interventional

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

NCT06142396
View directory record Official record
Conditions
Multiple Myeloma, Renal Failure
Interventions
Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
Combination Product
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 17, 2026, 10:19 AM EDT
Completed Phase 2 Interventional Results available

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

NCT00691015
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
rituximab, busulfan, carmustine, cyclophosphamide, cytarabine, etoposide, fludarabine phosphate, melphalan, total body irradiation (TBI), anti-thymocyte globulin IV
Biological · Drug · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 17, 2026, 10:19 AM EDT
Active, not recruiting Phase 4 Interventional

A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis

NCT05983068
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 14 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Denver, Colorado • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 17, 2026, 10:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of Menstrual Phase on Oral Glucose Sensitivity

NCT06800690
View directory record Official record
Conditions
Ovulation, Menstruation
Interventions
Urinary Estrogen Level
Diagnostic Test
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 46 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 17, 2026, 10:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Bioequivalence of a Combined Formulated Tablet

NCT01622790
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 17, 2026, 10:19 AM EDT
Completed Phase 1 Interventional

A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer

NCT00423410
View directory record Official record
Conditions
Advanced Cancer
Interventions
EPC2407 (crinobulin)
Drug
Lead sponsor
EpiCept Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • Beverly Hills, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2009 · Synced Oct 17, 2026, 10:19 AM EDT
Completed Phase 4 Interventional

Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children

NCT00522782
View directory record Official record
Conditions
Asthma
Interventions
Nebulized Budesonide, Nitric Oxide Analyzer
Drug · Device
Lead sponsor
AAADRS Clinical Research Center
Other
Eligibility
4 Years to 6 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2009 · Synced Oct 17, 2026, 10:19 AM EDT
Completed Phase 1 Interventional

A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies

NCT00923520
View directory record Official record
Conditions
Renal Cell Carcinoma, Breast Cancer, Colon Cancer, Lung Cancer, Non-Hodgkin Lymphoma
Interventions
DMS 612
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
3
States / cities
Bethesda, Maryland • Hershey, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 17, 2026, 10:19 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

NCT00814879
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections
Interventions
Raltegravir, Atazanavir, Standard treatment regimen
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
New Haven, Connecticut • Waterbury, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 17, 2026, 10:19 AM EDT
Terminated Phase 3 Interventional Results available

Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.

NCT01770379
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Secukinumab (AIN457), Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
25
States / cities
Peoria, Arizona • Santa Monica, California • Upland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 17, 2026, 10:19 AM EDT
Terminated Phase 2 Interventional Results available

Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

NCT02129062
View directory record Official record
Conditions
Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia
Interventions
Ibrutinib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 17, 2026, 10:19 AM EDT